JENNIFER WARD: Open Payments
NPI 1114648490 · TULLAHOMA, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,350 in 70 payments from 26 companies in 2025. Trend: 2023 $594 · 2024 $1,657 · 2025 $1,350
Food & beverage: $1,350
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $391 |
| Xeris Pharmaceuticals, Inc. | 10 | $200 |
| Novo Nordisk Inc | 6 | $111 |
| Lilly USA, LLC | 6 | $101 |
| Novartis Pharmaceuticals Corporation | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Alkermes, Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Amgen Inc. | 2 | $30 |
Products named: VRAYLAR, RECORLEV, QULIPTA, MOUNJARO, UBRELVY, GVOKE HYPOPEN, LEQVIO, Wegovy.
Industry payments across TN — which companies pay providers there.
